1. Advances in the prevention and treatment of breast cancer-related lymphedema

   • Paula M. C. Donahue
   • Adrien MacKenzie
   • Louise Koelmeyer

   Review Open access 27 April 2023 Pages: 1 - 14

   

2. Clinical efficacy of PARP inhibitors in breast cancer

   • Karan Pandya
   • Alyssa Scher
   • Mridula A. George

   Review 02 May 2023 Pages: 15 - 22

   

3. The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer

   • Jiayue Hu
   • Ronggang Lang
   • Yehui Shi

   Preclinical study Open access 09 May 2023 Pages: 23 - 36

   

4. Comparison of initial and sequential salvage brain-directed treatment in patients with 1–4 vs. 5–10 brain metastases from breast cancer (KROG 16–12)

   • Jae Sik Kim
   • Kyubo Kim
   • In Ah Kim

   Clinical trial 03 May 2023 Pages: 37 - 45

   

5. Clinical significance of microinvasive breast cancer across the different subtypes and human epidermal growth factor receptor 2 expression levels

   • Soo-Young Lee
   • Tae-Kyung Yoo
   • Sae Byul Lee

   Clinical trial 15 May 2023 Pages: 47 - 61

   

6. Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception

   • Brittany L. Bychkovsky
   • Min-Tzu Lo
   • Huma Q. Rana

   Epidemiology Open access 01 March 2023 Pages: 63 - 72

   

7. Correction to: Pathogenic variants among females with breast cancer and a non‑breast cancer reveal opportunities for cancer interception

   • Brittany L. Bychkovsky
   • Min-Tzu Lo
   • Huma Q. Rana

   Correction Open access 13 May 2023 Pages: 73 - 73

8. The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer

   • Elizabeth Terman
   • Jori Sheade
   • Rita Nanda

   Epidemiology Open access 29 April 2023 Pages: 75 - 83

   

9. Social determinants of health and CDK4/6 inhibitor use and outcomes among patients with metastatic breast cancer

   • Claire Sathe
   • Melissa K. Accordino
   • Dawn L. Hershman

   Epidemiology 08 May 2023 Pages: 85 - 92

   

10. Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32)

    • Dawn L. Hershman
    • Bingshu E. Chen
    • Pamela J. Goodwin

    Epidemiology 09 May 2023 Pages: 93 - 102

    

11. Breast cancer survivorship and sexual dysfunction: a population-based cohort study

    • Chun-Pin Chang
    • Tiffany F. Ho
    • Mia Hashibe

    Epidemiology 09 May 2023 Pages: 103 - 113

12. Nuclear magnetic resonance-determined lipoprotein profile and risk of breast cancer: a Mendelian randomization study

    • Jinyu Xiao
    • Yu Hao
    • Ben Zhang

    Epidemiology 10 May 2023 Pages: 115 - 126

    

13. Breast cancer treatment receipt and the role of financial stress, health literacy, and numeracy among diverse breast cancer survivors

    • Ashley Odai-Afotey
    • Ruth I. Lederman
    • Rachel A. Freedman

    Epidemiology 13 May 2023 Pages: 127 - 137

    

14. Premenopausal women with breast cancer in the early post-partum period show molecular profiles of invasion and are associated with poor prognosis

    • Vidya P. Nimbalkar
    • V. P. Snijesh
    • Jyothi S. Prabhu

    Original Laboratory Investigation Open access 09 May 2023 Pages: 139 - 149

    

15. Targeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34

    • Kristin A. Altwegg
    • Uday P. Pratap
    • Ratna K. Vadlamudi

    Original Laboratory Investigation Open access 18 May 2023 Pages: 151 - 162